The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 18, 2024

Filed:

Apr. 15, 2019
Applicants:

CZ Biohub Sf Llc, San Francisco, CA (US);

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Michael F. Clarke, Stanford, CA (US);

Neethan A. Lobo, Stanford, CA (US);

Maider Zabala Ugalde, Stanford, CA (US);

Jane Antony, Stanford, CA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 38/18 (2006.01); C07K 16/22 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); G01N 33/74 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1136 (2013.01); A61K 38/1808 (2013.01); A61K 38/1841 (2013.01); A61K 38/1875 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57484 (2013.01); G01N 33/74 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/495 (2013.01); G01N 2333/51 (2013.01); G01N 2500/02 (2013.01);
Abstract

This disclosure provides data showing that LEFTY inhibits differentiation-promoting pathways such as BMP7/pSMAD5 in breast cancer cell lines, over and above its known role of inhibiting Nodal/pSMAD2. LEFTY competes with BMP7 to bind to its cell surface receptor BMPR2, leading to inhibition of pSMAD5. The LEFTY-BMPR2 interaction is dominant over BMP-BMPR2 in tumorigenic cells, resulting in diminished pSMAD status, whereas in non-tumorigenic cells, there is minimal LEFTY-BMPR2 interaction, increased BMP7-BMPR2 association, and elevated pSMAD. Compositions and methods for inducing or inhibiting expression and/or the activity of LEFTY and BMP proteins are described, which can be used in diagnosis and therapy of cancer and other conditions, and to promote proliferation of stem cells.


Find Patent Forward Citations

Loading…